BDX Stock Analysis: Becton Dickinson | NYSE
Medical Instruments & Supplies | NYSE, USA | Market Cap: 50.070m USD | 12M Return: 24.7% | US0758871091 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 300M
EPS Trend: 67.8%
Qual. Beats: 0
Rev. Trend: 87.8%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Becton, Dickinson and Company (BDX) is a large-cap U.S. medical technology company that develops, manufactures, and sells a broad portfolio of medical supplies, devices, laboratory instruments, and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public worldwide. The company operates through four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional and Life Sciences.
Its product offerings span vascular access and infusion therapy products (IV catheters, central lines, needle-free connectors, infusion systems, pharmacy automation), drug delivery systems (prefillable syringes, closed-system drug transfer devices), diagnostics (automated blood and TB culturing, molecular testing, microbiology lab automation, clinical oncology and immunology reagents), life science research tools (flow cytometers, single-cell gene expression solutions), and surgical and interventional products (hernia and soft tissue repair, biosurgery, peripheral intervention, urology). BDX also maintains a strategic collaboration with ChemoGLO to advance hazardous drug contamination testing in healthcare settings.
As a diversified medical device manufacturer, BDX benefits from cross-selling opportunities across its four segments and a recurring revenue base driven by high-volume consumables such as syringes, needles, and blood collection products. The medical device industry is characterized by lengthy regulatory approval cycles, significant R&D investment, and stable demand tied to healthcare utilization rather than economic cycles. BDXs segment structure allows it to participate across the full continuum of care, from pharmaceutical development and bioprocessing through clinical diagnostics, drug delivery, and surgical intervention.
- Connected Care medication management revenue accelerates on hospital automation demand
- Interventional segment margins pressured by post-pandemic elective procedure normalization
- Prefillable syringe demand surges from GLP-1 obesity drug manufacturers
| Net Income: 941.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.49 > 1.0 |
| NWC/Revenue: -6.07% < 20% (prev 3.91%; Δ -9.98% < -1%) |
| CFO/TA 0.07 > 3% & CFO 3.33b > Net Income 941.0m |
| Net Debt (16.1b) to EBITDA (4.37b): 3.68 < 3 |
| Current Ratio: 0.87 > 1.5 & < 3 |
| Outstanding Shares: last quarter (275.2m) vs 12m ago -4.69% < -2% |
| Gross Margin: 46.12% > 18% (prev 44.95%; Δ 1.17% > 0.5%) |
| Asset Turnover: 39.46% > 50% (prev 38.95%; Δ 0.50% > 0%) |
| Interest Coverage Ratio: 3.77 > 6 (EBIT TTM 2.05b / Interest Expense TTM 543.0m) |
| A: -0.02 (Total Current Assets 8.14b - Total Current Liabilities 9.40b) / Total Assets 50.7b |
| B: 0.35 (Retained Earnings 17.5b / Total Assets 50.7b) |
| C: 0.04 (EBIT TTM 2.05b / Avg Total Assets 52.8b) |
| D: 0.93 (Book Value of Equity 24.4b / Total Liabilities 26.3b) |
| Altman-Z'' = 2.20 = BBB |
| DSRI: 0.82 (Receivables 2.36b/2.94b, Revenue 20.8b/21.4b) |
| GMI: 0.97 (GM 44.95% / 46.12%) |
| AQI: 1.01 (AQ_t 0.72 / AQ_t-1 0.71) |
| SGI: 0.97 (Revenue 20.8b / 21.4b) |
| TATA: -0.05 (NI 941.0m - CFO 3.33b) / TA 50.7b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of October 01, 2026, the stock is trading at USD 179.00 with a total of 1,788,240 shares traded. Over the past week, the price has changed by -1.93%, over one month by -4.28%, over three months by +18.98% and over the past year by +24.69%.
Current recommended Stop Loss: 174.10 (which is 2.7% or 1.2 ATR below the current price).
Becton Dickinson has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy BDX.
- StrongBuy: 6
- Buy: 1
- Hold: 9
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 195.7 | 9.3% |
P/E Trailing = 31.8579
P/E Forward = 13.7174
P/S = 2.2269
P/B = 2.0362
P/EG = 1.1074
Revenue TTM = 20.8b USD
EBIT TTM = 2.05b USD
EBITDA TTM = 4.37b USD
Long Term Debt = 13.5b USD (from longTermDebt, last quarter)
Short Term Debt = 3.30b USD (from shortTermDebt, last quarter)
Debt = 16.8b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 16.1b USD (calculated: Debt 16.8b - CCE 709.0m)
Enterprise Value = 66.2b USD (50.1b + Debt 16.8b - CCE 709.0m)
Interest Coverage Ratio = 3.77 (Ebit TTM 2.05b / Interest Expense TTM 543.0m)
EV/FCF = 25.39x (Enterprise Value 66.2b / FCF TTM 2.61b)
FCF Yield = 3.94% (FCF TTM 2.61b / Enterprise Value 66.2b)
FCF Margin = 12.51% (FCF TTM 2.61b / Revenue TTM 20.8b)
Net Margin = 4.52% (Net Income TTM 941.0m / Revenue TTM 20.8b)
Gross Margin = 46.12% ((Revenue TTM 20.8b - Cost of Revenue TTM 11.2b) / Revenue TTM)
Gross Margin QoQ = 46.46% (prev 45.69%)
Tobins Q-Ratio = 1.30 (Enterprise Value 66.2b / Total Assets 50.7b)
Interest Expense / Debt = 3.23% (Interest Expense 543.0m / Debt 16.8b)
Taxrate = 18.93% (301.0m / 1.59b)
NOPAT = 1.66b (EBIT 2.05b * (1 - 18.93%))
Current Ratio = 0.87 (Total Current Assets 8.14b / Total Current Liabilities 9.40b)
Debt / Equity = 0.69 (Debt 16.8b / totalStockholderEquity, last quarter 24.4b)
Debt / EBITDA = 3.68 (Net Debt 16.1b / EBITDA 4.37b)
Debt / FCF = 6.18 (Net Debt 16.1b / FCF TTM 2.61b)
Total Stockholder Equity = 24.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.78% (Net Income 941.0m / Total Assets 50.7b)
RoE = 3.79% (Net Income TTM 941.0m / Total Stockholder Equity 24.8b)
RoCE = 5.34% (EBIT 2.05b / Capital Employed (Equity 24.8b + L.T.Debt 13.5b))
RoIC = 3.78% (NOPAT 1.66b / Invested Capital 43.9b)
WACC = 5.97% (E(50.1b)/V(66.9b) * Re(7.09%) + D(16.8b)/V(66.9b) * Rd(3.23%) * (1-Tc(0.19)))
Discount Rate = 7.09% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -86.38 | Cagr: -2.36%
[DCF] Terminal Value 75.73% ; FCFF base≈2.58b ; Y1≈2.64b ; Y5≈2.90b
[DCF] Fair Price = 105.9 (EV 45.0b - Net Debt 16.1b = Equity 28.9b / Shares 272.4m; r=8.35% [WACC [floored]]; 5y FCF grow 2.20% → 2.50% )
EPS Correlation: 67.84 | EPS CAGR: 5.06% | SUE: 0.67 | # QB: 0
Revenue Correlation: 87.78 | Revenue CAGR: 4.34% | SUE: 1.41 | # QB: 1
EPS current Quarter (2026-12-31): EPS=2.73 | Chg30d=+0.08% | Revisions=-70% | Analysts=9
EPS current Year (2026-09-30): EPS=12.62 | Chg30d=+0.00% | Revisions=+79% | GrowthEPS=-12.3% | GrowthRev=-11.8%
EPS next Year (2027-09-30): EPS=13.29 | Chg30d=+0.00% | Revisions=-62% | GrowthEPS=+5.3% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: -13% (up=12, down=16)